The potential of metabolomic approaches for investigating mode(s) of action of xenobiotics: Case study with carbon tetrachloride

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 722, Issue 2, 2011, Pages 147-153

  Vulimiri, Suryanarayana V ^a   Berger, Alvin ^b   Sonawane, Babasaheb ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Carbon tetrachloride; Metabolomics; Mode of action; Xenobiotics

Indexed keywords

CARBON TETRACHLORIDE; XENOBIOTIC AGENT;

ADVERSE OUTCOME; ARTICLE; CYTOTOXICITY; GENOTOXICITY; HUMAN; INFLAMMATION; LIPID PEROXIDATION; METABOLOMICS; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ANIMALS; CARBON TETRACHLORIDE; CELL PROLIFERATION; CYTOTOXINS; DNA DAMAGE; HUMANS; INFLAMMATION; LIPID PEROXIDATION; METABOLOMICS; OXIDATIVE STRESS; TOXICITY TESTS; TOXICOLOGY; XENOBIOTICS;

ANIMALIA;

EID: 79957688504     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2010.02.013     Document Type: Article

References (94)

1. Rezen T., Contreras J.A., Rozman D. Functional genomics approaches to studies of the cytochrome p450 superfamily. Drug Metab. Rev. 2007, 39:389-399.
2. Oliver S.G., Winson M.K., Kell D.B., Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998, 16:373-378.
3. 2 for pharmaceutical and environmental analysis. Trends Anal. Chem. 2007, 26:625-636.
4. Cascante M., Marin S. Metabolomics and fluxomics approaches. Essays Biochem. 2008, 45:67-81.
5. Kanani H., Chrysanthopoulos P.K., Klapa M.I. Standardizing GC-MS metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871:191-201.
6. Chen C., Gonzalez F.J., Idle J.R. LC-MS-based metabolomics in drug metabolism. Drug Metab. Rev. 2007, 39:581-597.
7. Thomasson C.G., Blijenberg B.G., Eilers G.A., Leijnse B. A comparative study of five different methods for the determination of 3-methoxy-4-hydroxymandelic acid in urine. J. Clin. Chem. Clin. Biochem. 1983, 21:417-427.
8. Evans A.M., Dehaven C.D., Barrett T., Mitchell M., Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem. 2009.
9. Sun J., Schnackenberg L.K., Holland R.D., Schmitt T.C., Cantor G.H., Dragan Y.P., Beger R.D. Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871:328-340.
10. Lapainis T., Rubakhin S.S., Sweedler J.V. Capillary electrophoresis with electrospray ionization mass spectrometric detection for single-cell metabolomics. Anal. Chem. 2009, 81:5858-5864.
11. Rubino F.M., Pitton M., Di Fabio D., Colombi A. Toward an " omic" physiopathology of reactive chemicals: thirty years of mass spectrometric study of the protein adducts with endogenous and xenobiotic compounds. Mass Spectrom. Rev. 2009, 28:725-784.
12. Waldhier M.C., Gruber M.A., Dettmer K., Oefner P.J. Capillary electrophoresis and column chromatography in biomedical chiral amino acid analysis. Anal. Bioanal. Chem. 2009, 394:695-706.
13. Pauling L. Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 1968, 160:265-271.
14. Kinsella J.E. Pathogenesis of fatty liver-a postulated mechanism. Am. J. Clin. Nutr. 1966, 19:291-292.
15. Kinsella J.E. Metabolic patterns of the fatty acids of Periplanteta americana (L.) during its embryonic development. Can. J. Biochem. 1966, 44:247-258.
16. Pauling L., Robinson A.B., Teranishi R., Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:2374-2376.
17. Devaux P.G., Horning M.G., Hill R.M., Horning E.C. O-benzyloximes: derivatives for the study of ketosteroids by gas chromatography. Application to urinary steroids of the newborn human. Anal. Biochem. 1971, 41:70-82.
18. Gartland K.P., Sanins S.M., Nicholson J.K., Sweatman B.C., Beddell C.R., Lindon J.C. Pattern recognition analysis of high resolution 1H NMR spectra of urine. A nonlinear mapping approach to the classification of toxicological data. NMR Biomed. 1990, 3:166-172.
19. Gartland K.P., Beddell C.R., Lindon J.C., Nicholson J.K. Application of pattern recognition methods to the analysis and classification of toxicological data derived from proton nuclear magnetic resonance spectroscopy of urine. Mol. Pharmacol. 1991, 39:629-642.
20. Griffin J.L. Metabolic profiles to define the genome: can we hear the phenotypes?. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2004, 359:857-871.
21. Nicholson J.K., Wilson I.D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2003, 2:668-676.
22. Hojer-Pedersen J., Smedsgaard J., Nielsen J. Elucidating the mode-of-action of compounds from metabolite profiling studies. Prog. Drug Res. 2007, 64. 103, 105-129.
23. Griffin J.L. Understanding mouse models of disease through metabolomics. Curr. Opin. Chem. Biol. 2006, 10:309-315.
24. Shockcor J.P., Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2002, 2:35-51.
25. Lindon J.C., Keun H.C., Ebbels T.M., Pearce J.M., Holmes E., Nicholson J.K. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 2005, 6:691-699.
26. Lindon J.C., Nicholson J.K., Holmes E., Antti H., Bollard M.E., Keun H., Beckonert O., Ebbels T.M., Reily M.D., Robertson D., Stevens G.J., Luke P., Breau A.P., Cantor G.H., Bible R.H., Niederhauser U., Senn H., Schlotterbeck G., Sidelmann U.G., Laursen S.M., Tymiak A., Car B.D., Lehman-McKeeman L., Colet J.M., Loukaci A., Thomas C. Contemporary issues in toxicology. The role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 2003, 187:137-146.
27. Ebbels T.M., Keun H.C., Beckonert O.P., Bollard M.E., Lindon J.C., Holmes E., Nicholson J.K. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 2007, 6:4407-4422.
28. Cavill R., Keun H.C., Holmes E., Lindon J.C., Nicholson J.K., Ebbels T.M. Genetic algorithms for simultaneous variable and sample selection in metabonomics. Bioinformatics 2009, 25:112-118.
29. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2009.
30. Jacobs A. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol. Lett. 2009, 186:32-35.
31. Cowart L.A., Hannun Y.A. Using genomic and lipidomic strategies to investigate sphingolipid function in the yeast heat-stress response. Biochem. Soc. Trans. 2005, 33:1166-1169.
32. Boros L.G., Brackett D.J., Harrigan G.G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr. Cancer Drug Targets 2003, 3:445-453.
33. Zhang J., Herman E.H., Robertson D.G., Reily M.D., Knapton A., Ratajczak H.V., Rifai N., Honchel R., Blanchard K.T., Stoll R.E., Sistare F.D. Mechanisms and biomarkers of cardiovascular injury induced by phosphodiesterase inhibitor III SK&F 95654 in the spontaneously hypertensive rat. Toxicol. Pathol. 2006, 34:152-163.
34. Ohta T., Masutomi N., Tsutsui N., Sakairi T., Mitchell M., Milburn M.V., Ryals J.A., Beebe K.D., Guo L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol. Pathol. 2009, 37:521-535.
35. Boudonck K.J., Mitchell M.W., Nemet L., Keresztes L., Nyska A., Shinar D., Rosenstock M. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 2009, 37:280-292.
36. Atherton H.J., Gulston M.K., Bailey N.J., Cheng K.K., Zhang W., Clarke K., Griffin J.L. Metabolomics of the interaction between PPAR-α and age in the PPAR-α-null mouse. Mol. Syst. Biol. 2009, 5:259.
37. Alakoskela J.M., Vitovic P., Kinnunen P.K. Screening for the drug-phospholipid interaction: correlation to phospholipidosis. ChemMedChem 2009, 4:1224-1251.
38. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
39. Fave G., Beckmann M.E., Draper J.H., Mathers J.C. Measurement of dietary exposure: a challenging problem which may be overcome thanks to metabolomics?. Genes Nutr. 2009.
40. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr. Metab. Cardiovasc. Dis. 2009.
41. Barnes V.M., Teles R., Trivedi H.M., Devizio W., Xu T., Mitchell M.W., Milburn M.V., Guo L. Acceleration of purine degradation by periodontal diseases. J. Dent. Res. 2009, 88:851-855.
42. Ellis D.I., Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 2006, 131:875-885.
43. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
44. Watson M., Roulston A., Belec L., Billot X., Marcellus R., Bedard D., Bernier C., Branchaud S., Chan H., Dairi K., Gilbert K., Goulet D., Gratton M.O., Isakau H., Jang A., Khadir A., Koch E., Lavoie M., Lawless M., Nguyen M., Paquette D., Turcotte E., Berger A., Mitchell M., Shore G.C., Beauparlant P. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell Biol. 2009, 29:5872-5888.
45. U.S.EPA Guidelines for carcinogen risk assessment. Federal Register 2005, 70:17765-17817.
46. van Ravenzwaay B., Cunha G.C., Leibold E., Looser R., Mellert W., Prokoudine A., Walk T., Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 2007, 172:21-28.
47. Chen C., Krausz K.W., Idle J.R., Gonzalez F.J. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 2008, 283:4543-4559.
48. Vulimiri S.V., Misra M., Hamm J.T., Mitchell M., Berger A. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem. Res. Toxicol. 2009, 22:492-503.
49. Guyton K.Z., Kyle A.D., Aubrecht J., Cogliano V.J., Eastmond D.A., Jackson M., Keshava N., Sandy M.S., Sonawane B., Zhang L., Waters M.D., Smith M.T. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat. Res. 2009, 681:230-240.
50. Heijne W.H., Kienhuis A.S., van Ommen B., Stierum R.H., Groten J.P. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics 2005, 2:767-780.
51. Ganter B., Zidek N., Hewitt P.R., Muller D., Vladimirova A. Pathway analysis tools and toxicogenomics reference databases for risk assessment. Pharmacogenomics 2008, 9:35-54.
52. Eastmond D.A. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: a case study involving carbon tetrachloride. Environ. Mol. Mutagen. 2008, 49:132-141.
53. Manibusan M.K., Odin M., Eastmond D.A. Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2007, 25:185-209.
54. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003, 33:105-136.
55. Catala A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 2009, 157:1-11.
56. De Zwart L.L., Venhorst J., Groot M., Commandeur J.N., Hermanns R.C., Meerman J.H., Van Baar B.L., Vermeulen N.P. Simultaneous determination of eight lipid peroxidation degradation products in urine of rats treated with carbon tetrachloride using gas chromatography with electron-capture detection. J. Chromatogr. B Biomed. Sci. Appl. 1997, 694:277-287.
57. Gee D.L., Bechtold M.M., Tappel A.L. Carbon tetrachloride-induced lipid peroxidation: simultaneous in vivo measurements of pentane and chloroform exhaled by the rat. Toxicol. Lett. 1981, 8:299-306.
58. Hwang E.S., Kim G.H. Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. Toxicology 2007, 229:1-10.
59. Shibamoto T. Analytical methods for trace levels of reactive carbonyl compounds formed in lipid peroxidation systems. J. Pharm. Biomed. Anal. 2006, 41:12-25.
60. Yuan L., Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 2009, 30:29-41.
61. Forman H.J., Zhang H., Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol. Aspects Med. 2009, 30:1-12.
62. Cabre M., Camps J., Paternain J.L., Ferre N., Joven J. Time-course of changes in hepatic lipid peroxidation and glutathione metabolism in rats with carbon tetrachloride-induced cirrhosis. Clin. Exp. Pharmacol. Physiol. 2000, 27:694-699.
63. Ichi I., Kamikawa C., Nakagawa T., Kobayashi K., Kataoka R., Nagata E., Kitamura Y., Nakazaki C., Matsura T., Kojo S. Neutral sphingomyelinase-induced ceramide accumulation by oxidative stress during carbon tetrachloride intoxication. Toxicology 2009, 261:33-40.
64. Mena S., Ortega A., Estrela J.M. Oxidative stress in environmental-induced carcinogenesis. Mutat. Res. 2009, 674:36-44.
65. Beddowes E.J., Faux S.P., Chipman J.K. Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology 2003, 187:101-115.
66. Kwolek-Mirek M., Bednarska S., Bartosz G., Bilinski T. Acrolein toxicity involves oxidative stress caused by glutathione depletion in the yeast Saccharomyces cerevisiae. Cell Biol. Toxicol. 2008.
67. Tsai-Turton M., Luong B.T., Tan Y., Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol. Sci. 2007, 98:216-230.
68. Ellouk-Achard S., Levresse V., Martin C., Pham-Huy C., Dutertre-Catella H., Thevenin M., Warnet J.M., Claude J.R. Ex vivo and in vitro models in acetaminophen hepatotoxicity studies. Relationship between glutathione depletion, oxidative stress and disturbances in calcium homeostasis and energy metabolism. Arch. Toxicol. Suppl. 1995, 17:209-214.
69. Kumar P., Prasad A.K., Maji B.K., Mani U., Dutta K.K. Hepatoxic alterations induced by inhalation of trichlorethylene (TCE) in rats. Biomed. Environ. Sci. 2001, 14:325-332.
70. Phimister A.J., Lee M.G., Morin D., Buckpitt A.R., Plopper C.G. Glutathione depletion is a major determinant of inhaled naphthalene respiratory toxicity and naphthalene metabolism in mice. Toxicol. Sci. 2004, 82:268-278.
71. Nakagawa I., Suzuki M., Imura N., Naganuma A. Involvement of oxidative stress in paraquat-induced metallothionein synthesis under glutathione depletion. Free Radic. Biol. Med. 1998, 24:1390-1395.
72. Lin Y., Si D., Zhang Z., Liu C. An integrated metabonomic method for profiling of metabolic changes in carbon tetrachloride induced rat urine. Toxicology 2009, 256:191-200.
73. Kim K.-B., Chung M.W., Um S.Y., Oh J.S., Kim S.H., Na M.A., Oh H.Y., Cho W.-S., Choi K.H. Metabolomics and biomarker discovery: NMR spectral data of urine and hepatotoxicity by carbon tetrachloride, acetaminophen, and d-galactosamine in rats. Metabolomics 2008, 4:377-392.
74. 4-induced acute liver failure using partial least square regression based on the GC/MS metabolic profiles of plasma in mice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 870:178-185.
75. Robertson D.G., Reily M.D., Sigler R.E., Wells D.F., Paterson D.A., Braden T.K. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 2000, 57:326-337.
76. Sun F., Hamagawa E., Tsutsui C., Ono Y., Ogiri Y., Kojo S. Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. Biochim. Biophys. Acta 2001, 1535:186-191.
77. Harvey P.J., Gready J.E., Hickey H.M., Le Couteur D.G., McLean A.J. 31P and 1H NMR spectroscopic studies of liver extracts of carbon tetrachloride-treated rats. NMR Biomed. 1999, 12:395-401.
78. Wang C., Yang J., Nie J. Plasma phospholipid metabolic profiling and biomarkers of rats following radiation exposure based on liquid chromatography-mass spectrometry technique. Biomed. Chromatogr. 2009.
79. Luster M.I., Simeonova P.P., Gallucci R.M., Bruccoleri A., Blazka M.E., Yucesoy B. Role of inflammation in chemical-induced hepatotoxicity. Toxicol. Lett. 2001, 120:317-321.
80. Basu S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology 2003, 189:113-127.
81. Serhan C.N. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 2009, 7 Suppl. 1:44-48.
82. Liu J.Y., Tsai H.J., Hwang S.H., Jones P.D., Morisseau C., Hammock B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br. J. Pharmacol. 2009, 156:284-296.
83. Buczynski M.W., Dumlao D.S., Dennis E.A. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 2009, 50:1015-1038.
84. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981, 19:1-20.
85. Luk G.D. Essential role of polyamine metabolism in hepatic regeneration. Inhibition of deoxyribonucleic acid and protein synthesis and tissue regeneration by difluoromethylornithine in the rat. Gastroenterology 1986, 90:1261-1267.
86. Pegg A.E., Matsui I., Seely J.E., Pritchard M.L., Poso H. Formation of putrescine in rat liver. Med. Biol. 1981, 59:327-333.
87. Ducros V., Ruffieux D., Belva-Besnet H., de Fraipont F., Berger F., Favier A. Determination of dansylated polyamines in red blood cells by liquid chromatography-tandem mass spectrometry. Anal. Biochem. 2009, 390:46-51.
88. Barbin A. Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. Mutat. Res. 2000, 462:55-69.
89. Goetz M.E., Luch A. Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett. 2008, 266:73-83.
90. Nair U., Bartsch H., Nair J. Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. Free Radic. Biol. Med. 2007, 43:1109-1120.
91. Chung H., Hong D.P., Kim H.J., Jang K.S., Shin D.M., Ahn J.I., Lee Y.S., Kong G. Differential gene expression profiles in the steatosis/fibrosis model of rat liver by chronic administration of carbon tetrachloride. Toxicol. Appl. Pharmacol. 2005, 208:242-254.
92. Chung H., Hong D.P., Jung J.Y., Kim H.J., Jang K.S., Sheen Y.Y., Ahn J.I., Lee Y.S., Kong G. Comprehensive analysis of differential gene expression profiles on carbon tetrachloride-induced rat liver injury and regeneration. Toxicol. Appl. Pharmacol. 2005, 206:27-42.
93. Fountoulakis M., de Vera M.C., Crameri F., Boess F., Gasser R., Albertini S., Suter L. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol. Appl. Pharmacol. 2002, 183:71-80.
94. Tang J., Tan C.Y., Oresic M., Vidal-Puig A. Integrating post-genomic approaches as a strategy to advance our understanding of health and disease. Genome Med. 2009, 1:35.